Theranica, a neuromodulation therapeutics company, is exhibiting and presenting at the upcoming 52nd Annual Child Neurology Society Meeting (CNS)(Booth #209), where they will present Nerivio®, the first and only dual-use (acute and preventive) migraine neuroband purpose-built for adolescents with migraine disease.
| |
| [28-September-2023] |
| Theranica to Unveil Groundbreaking New Real-World Data for Nerivio®, a Novel Drug-Free Device for Acute and Preventive Treatment of Migraine NETANYA, Israel and BRIDGEWATER, N.J., Sept. 28, 2023 /PRNewswire/ -- Theranica, a neuromodulation therapeutics company, is exhibiting and presenting at the upcoming 52nd Annual Child Neurology Society Meeting (CNS)(Booth #209), where they will present Nerivio®, the first and only dual-use (acute and preventive) migraine neuroband purpose-built for adolescents with migraine disease.
“Due to limited prescription medications in the treatment of migraine disease in children and adolescents, it is important to have safe and well-tolerated non-medication options,” says Rashmi Rao, MD, Pediatric Neurologist at Louisiana State University Health Sciences Center/Children’s Hospital New Orleans. “Reducing disability and frequency of migraine attacks in children and adolescents improves their quality of life and potentially decreases risk of conversion to chronic migraine. The recent expanded indication of the Nerivio migraine neuroband represents a distinctive dual-use treatment to reduce the occurrence of migraine episodes and relief their symptoms upon onset.” Migraine disease affects 1 billion people worldwide, 10 percent of which are children, with far-reaching consequences that can’t be ignored. Many prescription medications used for migraine treatment were not originally developed for or evaluated in adolescents, and they often come with poor tolerability and disruptive side effects. Migraine attacks can result in school absenteeism, loss of ability to participate in peer activities, and long-term psychosocial consequences. Living with migraine disease has a significant negative impact on the well-being of adolescents. According to Alon Ironi, the CEO and co-founder of Theranica, “Our goal at Theranica has always been focused on addressing significant unmet clinical needs. We’ve taken a simple approach: address the problem without creating new ones, and focus on developing migraine therapy that’s safe, easy to use, and is proven to work in adolescents. As a father of a daughter diagnosed with migraine, I was personally determined to achieve this goal.” “At this year’s CNS Meeting, we will present new clinical data that shows how the Nerivio migraine neuroband can empower adolescents to safely and effectively prevent and treat migraine, allowing them to fully participate in daily activities,” explained Alit Stark-Inbar, Theranica’s Vice President of Medical Information. “Massive real-world evidence continues to demonstrate how Nerivio can provide a personalized foundation for complete a migraine care as adolescents transition into adulthood.” CNS Product Theater Dr. Marielle Kabboche Samaha, Director, Acute and Inpatient Headache Program at Cincinnati Children’s Hospital, will be presenting on the burden of migraines on adolescents and their families. Dr. Rashmi Rao will provide a detailed overview of the clinical aspects of approved treatments for migraine disease in adolescents, including remote electrical neuromodulation (REN) with Nerivio, that induces the body’s conditioned pain modulation (CPM) response. Poster Presentation
Two guided poster tours will be held on Thursday, October 5th in the exhibit hall, one at 12:30 PM – 2:00 PM, and the other at 5:30 PM – 7:00 PM (Including Wine & Cheese). About the Nerivio Migraine Neuroband About Theranica Theranica Contact Media Contact
SOURCE Theranica |
View original content to download multimedia:
